Track the MESOBLAST LTD share price and the full management transaction log of the company, a listed equity based in United States. Shares trade on the US market, under the authority of SEC (Form 4). Market capitalisation: €2.2bn. The latest transaction was disclosed on 13 April 2026 (Acquisition). Among the most active insiders: George Gregory. All data is openly available.
30
Insider Decl.
n/a
Thresholds
€32m
30 ops.
Buy Volume
n/a
n/a
Sell Volume
22Σ signal
Buys €32mn/a Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 20,413 of 29,062 companies
38.2
score / 100
Value
26
Quality
50
FCF yld-2.3%
Earn yld-4.6%
EV/EBITDA·
ROE-18%
Gross mgn70%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
4,000,000 shares@ US$1.4215.3% of flowOrdinary SharesSEC:0001999371-26-008124:0
Canonical exit: 3 Jul 2026 (T+90)
25 of 30 declarations
Acerca de MESOBLAST LTD
MESOBLAST LTD es una empresa biofarmacéutica centrada en el desarrollo de terapias celulares para enfermedades graves. Cotiza en el NASDAQ bajo el símbolo MSB.